(Q33964432)

30 July 2017

1 reference

title

Moclobemide: therapeutic use and clinical studies (English)

1 reference

30 July 2017

Udo Bonnet

1

1 reference

30 July 2017

1 January 2003

1 reference

CNS Neuroscience & Therapeutics

30 July 2017

1 reference

30 July 2017

9

1 reference

30 July 2017

1

1 reference

30 July 2017

97-140

1 reference

Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression

30 July 2017

1 reference

12 December 2020

Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement

1 reference

12 December 2020

Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies

1 reference

12 December 2020

Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial.

1 reference

12 December 2020

Fatal combined intoxication with new antidepressants. Human cases and an experimental study of postmortem moclobemide redistribution

1 reference

12 December 2020

Social phobia: diagnosis, severity and implications for treatment

1 reference

12 December 2020

Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.

1 reference

12 December 2020

The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder.

1 reference

12 December 2020

Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease

1 reference

12 December 2020

Moclobemide in patients with dementia and depression

1 reference

12 December 2020

Serotonin syndrome caused by overdose with paroxetine and moclobemide

1 reference

12 December 2020

The effect of augmentation with moclobemide on symptoms of schizophrenia

1 reference

12 December 2020

Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia.

1 reference

12 December 2020

Precision and comparability of adverse event rates of newer antidepressants

1 reference

12 December 2020

Management of nonresponse and intolerance: switching strategies.

1 reference

12 December 2020

Augmentation strategies in depression 2000.

1 reference

12 December 2020

Clinical issues in long-term treatment with antidepressants.

1 reference

12 December 2020

Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury

1 reference

12 December 2020

Moclobemide reduces intracellular pH and neuronal activity of CA3 neurones in guinea-pig hippocampal slices-implication for its neuroprotective properties

1 reference

12 December 2020

Comparison of moclobemide with selective serotonin reuptake inhibitors (SSRIs) on sexual function in depressed adults. The Australian and German Study Groups.

1 reference

12 December 2020

Open comparative randomised study of moclobemide versus amitriptyline in major depressive illness (DSM IIIR) in Nigeria.

1 reference

12 December 2020

Efficacy and tolerability of moclobemide in bulimia nervosa: a placebo-controlled trial

1 reference

12 December 2020

Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction

1 reference

12 December 2020

A randomized controlled trial comparing moclobemide and moclobemide plus interpersonal psychotherapy in the treatment of dysthymic disorder

1 reference

12 December 2020

A fatal case of serotonin syndrome after combined moclobemide-citalopram intoxication

1 reference

12 December 2020

Moclobemide in pregnancy

1 reference

12 December 2020

Combining psychotherapy and antidepressants in the treatment of depression

1 reference

12 December 2020

Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans

1 reference

12 December 2020

Clinically significant drug interactions with agents specific for migraine attacks

1 reference

12 December 2020

Effects of moclobemide on sexual performance and nocturnal erections in psychogenic erectile dysfunction

1 reference

12 December 2020

Moclobemide vs. imipramine in bipolar depression: a multicentre double-blind clinical trial

1 reference

12 December 2020

Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.

1 reference

12 December 2020

Controlled comparison of RO 11-1163 (moclobemide) and placebo in the treatment of depression

1 reference

12 December 2020

Efficacy of moclobemide in different patient groups: a meta-analysis of studies

1 reference

12 December 2020

Biochemical effects of high single doses of moclobemide in man: correlation with plasma concentrations

1 reference

12 December 2020

Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness

1 reference

12 December 2020

Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine

1 reference

12 December 2020

Five-year outcome for maintenance therapies in recurrent depression

1 reference

12 December 2020

An Australian Multicentre Study of Moclobemide versus Amitriptyline in the Treatment of Depression

1 reference

12 December 2020

Clinical use of moclobemide in Kleine-Levin syndrome

1 reference

12 December 2020

A rating scale for depression

1 reference

12 December 2020

Abuse of monoamine oxidase inhibitors

1 reference

12 December 2020

The effects of paroxetine, alone and in combination with alcohol on psychomotor performance and cognitive function in the elderly

1 reference

12 December 2020

Efficacy and tolerability of moclobemide compared with fluvoxamine in depressive disorder (DSM III). A French/Swiss double-blind trial

1 reference

12 December 2020

Moclobemide and placebo in mild major depression: a double-blind randomized trial

1 reference

12 December 2020

A double-blind comparison of moclobemide and amineptine in the treatment of depressed out-patients

1 reference

12 December 2020

A double-blind comparison of moclobemide and toloxatone in out-patients presenting a major depressive disorder

1 reference

12 December 2020

Safety of moclobemide taken in overdose for attempted suicide

1 reference

12 December 2020

Post-stroke depression

1 reference

12 December 2020

Use of moclobemide in children with attention deficit hyperactivity disorder

1 reference

12 December 2020

Depression and senile dementia of the Alzheimer type: a role for moclobemide

1 reference

12 December 2020

Interactions of moclobemide with concomitantly administered medication: evidence from pharmacological and clinical studies

1 reference

12 December 2020

Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine

1 reference

12 December 2020

Influence of moclobemide on ibuprofen-induced faecal blood loss

1 reference

12 December 2020

Behavioural toxicity of antidepressants with particular reference to moclobemide

1 reference

12 December 2020

Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline

1 reference

12 December 2020

Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo

1 reference

12 December 2020

A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study

1 reference

12 December 2020

Antidepressants and the risk of seizures

1 reference

12 December 2020

Phenelzine vs atenolol in social phobia. A placebo-controlled comparison

1 reference

12 December 2020

Moclobemide versus clomipramine in endogenous depression. A double-blind randomised clinical trial

1 reference

12 December 2020

Peripheral oedema associated with moclobemide

1 reference

12 December 2020

Successful Treatment of Tardive Akathisia with Moclobemide, a Reversible and Selective Monoamine-Oxidase-A Inhibitor

1 reference

12 December 2020

Moclobemide in depression: a randomized, multicentre trial against isocarboxazide and clomipramine emphasizing atypical depression

1 reference

12 December 2020

Dependence on monoamine oxidase inhibitors in high dose

1 reference

12 December 2020

Multicenter study comparing efficacy and tolerance of moclobemide and fluvoxamine in hospitalized and ambulatory patients with severe depressive episodes

1 reference

12 December 2020

Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study.

1 reference

12 December 2020

Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide

1 reference

12 December 2020

The serotonin syndrome

1 reference

12 December 2020

Monoamine oxidase inhibitor interactions with other drugs.

1 reference

12 December 2020

A double blind trial of moclobemide versus amitriptyline in the treatment of depressive disorders

1 reference

12 December 2020

Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo

1 reference

12 December 2020

Double-blind comparison of moclobemide, imipramine and placebo in depressive patients

1 reference

12 December 2020

Moclobemide (Ro 11-1163) in long-term treatment

1 reference

12 December 2020

Clinical features, pathogenesis and management of drug-induced seizures

1 reference

12 December 2020

Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression

1 reference

12 December 2020

Moclobemide versus placebo in the treatment of depression: a multicentre study in Belgium.

1 reference

12 December 2020

Moclobemide (Ro 11-1163) versus desipramine in the treatment of endogenous depression

1 reference

12 December 2020

Moclobemide versus clomipramine in the treatment of depression: a single-centre study, Federal Republic of Germany

1 reference

12 December 2020

Moclobemide versus clomipramine in the treatment of depression: a multicentre trial in Spain

1 reference

12 December 2020

Moclobemide versus clomipramine in the treatment of depression: a double-blind multicentre study in Belgium

1 reference

12 December 2020

Moclobemide compared with second-generation antidepressants in elderly people

1 reference

12 December 2020

Moclobemide (Ro 11-1163) safety in depressed patients

1 reference

12 December 2020

Interaction studies with moclobemide

1 reference

12 December 2020

Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function

1 reference

12 December 2020

Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans

1 reference

12 December 2020

Evaluation and comparison of the interaction between alcohol and moclobemide or clomipramine in healthy subjects.

1 reference

12 December 2020

Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function

1 reference

12 December 2020

A Comparison of Moclobemide and Imipramine in Treatment of Depression

1 reference

12 December 2020

Moclobemide and clomipramine in endogenous depression. A randomized clinical trial

1 reference

12 December 2020

Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial

1 reference

12 December 2020

Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.

1 reference

12 December 2020

Moclobemide and maprotiline in the treatment of inpatients with major depressive disorder

1 reference

12 December 2020

Review of comparative clinical trials. Moclobemide vs tricyclic antidepressants and vs placebo in depressive states

1 reference

12 December 2020

The effects of moclobemide on cognition

1 reference

12 December 2020

A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes

1 reference

12 December 2020

Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.

1 reference

12 December 2020

The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors

1 reference

12 December 2020

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

12 December 2020

The prophylactic efficacy of fluoxetine in unipolar depression

1 reference

12 December 2020

A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness

1 reference

12 December 2020

Tyramine pressor effect in man: studies with moclobemide, a novel, reversible monoamine oxidase inhibitor.

1 reference

12 December 2020

Tranylcypromine in social phobia.

1 reference

12 December 2020

Monoamine oxidase inhibitors and anaesthesia. A review

1 reference

12 December 2020

On tyramine, food, beverages and the reversible MAO inhibitor moclobemide

1 reference

12 December 2020

Antidepressant drug therapy: associated risks.

1 reference

12 December 2020

Pharmacotherapy of social phobia: an interim report of a placebo-controlled comparison of phenelzine and atenolol

1 reference

12 December 2020

The jitteriness syndrome in panic disorder patients treated with antidepressants

1 reference

12 December 2020

A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety

1 reference

12 December 2020

Classification of Depressed Patients: A Cluster Analysis Derived Grouping

1 reference

12 December 2020

A Placebo-controlled Study of the Antidepressant Activity of Moclobemide,A New MAO-A Inhibitor

1 reference

12 December 2020

Moclobemide and clomipramine in the treatment of depression. A randomized clinical trial

1 reference

12 December 2020

Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine re-uptake inhibitors

1 reference

12 December 2020

Platelet monoamine oxidase activity in children and adolescents with psychiatric disorders.

1 reference

12 December 2020

Fatal serotonin syndrome following a combined overdose of moclobemide, clomipramine and fluoxetine

1 reference

12 December 2020

Clozapine-induced hypotension treated with moclobemide and Bovril

1 reference

12 December 2020

A controlled double-blind trial of moclobemide and imipramine in the treatment of depression

1 reference

12 December 2020

A double-blind comparison of moclobemide and doxepin in depressed general practice patients

1 reference

12 December 2020

The Loss of the Therapeutic Effect of Antidepressant Medication

1 reference

12 December 2020

A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers

1 reference

12 December 2020

Moclobemide and tricyclic antidepressants in severe depression: meta-analysis and prospective studies

1 reference

12 December 2020

Moclobemide versus clomipramine in depressed patients in general practice. A randomized, double-blind, parallel, multicenter study

1 reference

12 December 2020

Moclobemide for depression: an Australian psychiatric practice study

1 reference

12 December 2020

Moclobemide versus fluoxetine in the treatment of inpatients with major depression.

1 reference

12 December 2020

A double-blind comparison of moclobemide and thioridazine versus moclobemide and placebo in the treatment of refractory, severe depression.

1 reference

12 December 2020

The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson's disease

1 reference

12 December 2020

1 reference

12 December 2020

The behavioral toxicity of reversible inhibitors of monoamine oxidase A: laboratory and clinical investigations

1 reference

12 December 2020

Moclobemide safety: monitoring a newly developed product in the 1990s

1 reference

12 December 2020

Moclobemide: relationships between dose, drug concentration in plasma, and occurrence of adverse events

1 reference

12 December 2020

Moclobemide versus fluoxetine for a major depressive episode

1 reference

12 December 2020

Safety of antidepressants

1 reference

12 December 2020

Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression.

1 reference

12 December 2020

A case of moclobemide-induced hyperorgasmia.

1 reference

12 December 2020

Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy

1 reference

12 December 2020

Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor

1 reference

12 December 2020

Moclobemide and nortriptyline in elderly depressed patients. A randomized, multicentre trial against placebo

1 reference

12 December 2020

Studies of reversible and selective inhibitors of monoamine oxidase A in dysthymia.

1 reference

12 December 2020

Possible serotonin syndrome with moclobemide and pethidine.

1 reference

12 December 2020

Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study*

1 reference

12 December 2020

The safety of concomitant use of sumatriptan and antidepressant treatments

1 reference

12 December 2020

Moclobemide and fluoxetine in atypical depression: a double-blind trial.

1 reference

12 December 2020

Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses

1 reference

12 December 2020

Moclobemide twice daily in the treatment of major depressive episode: a double-blind, multicenter comparison with different three-times-daily dosage schedules.

1 reference

12 December 2020

Comparison of the efficacy and tolerability of moclobemide and maprotiline in depressed patients treated by general practitioners

1 reference

12 December 2020

Multicenter double-blind study of moclobemide and maprotiline

1 reference

12 December 2020

Moclobemide versus fluoxetine for major depressive episodes

1 reference

12 December 2020

Effects of moclobemide on depressive symptoms and cognitive performance in a geriatric population: a controlled comparative study versus imipramine.

1 reference

12 December 2020

Safety and efficacy during long-term treatment with moclobemide

1 reference

12 December 2020

Moclobemide in social phobia: a pilot open study. GRP Group. Groupe de Recherche en Psychopharmacologie

1 reference

12 December 2020

Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure

1 reference

12 December 2020

Anaesthesia and the new generation monoamine oxidase inhibitors.

1 reference

12 December 2020

Antidepressant efficacy and quality of life in depression: a double-blind study with moclobemide and fluoxetine.

1 reference

12 December 2020

Double-blind comparison of moclobemide and tranylcypromine in depression

1 reference

12 December 2020

Efficacy and safety of moclobemide compared with maprotiline in treatment of major depressive disorder. A double-blind multicenter study with parallel groups

1 reference

12 December 2020

Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver

1 reference

12 December 2020

Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings.

1 reference

12 December 2020

Specific issues in the cognitive-behavioral treatment of social phobia

1 reference

12 December 2020

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

1 reference

12 December 2020

The prevalence of dementia, depression and neurosis in later life: the Liverpool MRC-ALPHA Study.

1 reference

12 December 2020

A quantitative analysis of clinical drug trials for the treatment of affective disorders

1 reference

12 December 2020

Combined SSRI-moclobemide treatment of psychiatric illness.

1 reference

12 December 2020

Efficacy of moclobemide in different patient groups. Results of new subscales of the Hamilton Depression Rating Scale

1 reference

12 December 2020

Safety of moclobemide in clinical use.

1 reference

12 December 2020

The potential effectiveness of moclobemide, the new monoamine oxidase inhibitor, in the prophylaxis of migraine

1 reference

12 December 2020

Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

Do reversed depressive symptoms occur together as a syndrome?

1 reference

12 December 2020

Serotonin syndrome caused by a moclobemide-clomipramine interaction

1 reference

12 December 2020

Moclobemide versus imipramine in depressed out-patients: a double-blind multi-centre study

1 reference

12 December 2020

A comparison study of moclobemide and doxepin in major depression with special reference to effects on sexual dysfunction

1 reference

12 December 2020

A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders.

1 reference

12 December 2020

A randomized, double-blind, multi-centre, parallel-group study comparing the tolerability and efficacy of moclobemide and dothiepin hydrochloride in depressed patients in general practice

1 reference

12 December 2020

An update of recent moclobemide interaction data

1 reference

12 December 2020

Moclobemide and sertraline in the treatment of depressive disorders: a comparative study.

1 reference

12 December 2020

Therapeutic efficacy of antidepressants in agitated anxious depression--a meta-analysis of moclobemide studies

1 reference

12 December 2020

Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide

1 reference

12 December 2020

Intrahepatic cholestasis associated with moclobemide leading to death.

1 reference

12 December 2020

Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers

1 reference

12 December 2020

An open study with reversible MAO-A inhibitors in complicated Parkinson's disease

1 reference

12 December 2020

Three suicide attempts with moclobemide

1 reference

12 December 2020

Antidepressant-associated fatal intrahepatic cholestasis

1 reference

12 December 2020

Severe adverse reaction to moclobemide

1 reference

12 December 2020

Moclobemide in the prophylactic treatment of migraine. A retrospective analysis of 44 cases

1 reference

12 December 2020

Monoamine oxidase inhibitors. An update on drug interactions

1 reference

12 December 2020

A comparison of the effects of phenelzine treatment with moclobemide treatment on cardiovascular reflexes

1 reference

12 December 2020

Serotonin syndrome in the elderly after antidepressive monotherapy

1 reference

12 December 2020

The role of personality factors in the reporting of side effect complaints to moclobemide and placebo: a study of healthy male and female volunteers

1 reference

12 December 2020

Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial.

1 reference

12 December 2020

Moclobemide versus clomipramine in nonmelancholic, nonpsychotic major depression. A Study group

1 reference

12 December 2020

Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline

1 reference

12 December 2020

Serotonin syndrome with moclobemide-fluoxetine combination

1 reference

12 December 2020

Investigation of the effects of moclobemide in chronic ethanol feeding rats

1 reference

12 December 2020

Moclobemide. An update of its pharmacological properties and therapeutic use

1 reference

12 December 2020

The effects of moclobemide on sexual desire and function in healthy volunteers.

1 reference

12 December 2020

The role of cytochrome P450 2D6 in the metabolism of moclobemide

1 reference

12 December 2020

Pharmacokinetic-pharmacodynamic interactions between two selective monoamine oxidase inhibitors: moclobemide and selegiline

1 reference

12 December 2020

Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients

1 reference

12 December 2020

Moclobemide in the treatment of social phobia

1 reference

12 December 2020

Moclobemide and fluoxetine in treatment of seasonal affective disorder

1 reference

12 December 2020

Moclobemide versus fluoxetine for double depression: a randomized double-blind study.

1 reference

12 December 2020

Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults

1 reference

12 December 2020

Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.

1 reference

12 December 2020

Cognitive-behavioral therapy for panic disorder: current status.

1 reference

12 December 2020

The International Multicenter Clinical Trial Group on Moclobemide in Social Phobia. Moclobemide in social phobia. A double-blind, placebo-controlled clinical study

1 reference

12 December 2020

Combination therapy using moclobemide with tricyclic and tetracyclic antidepressants to treat therapy-resistant depression.

1 reference

12 December 2020

Efficacy issues with antidepressants.

1 reference

12 December 2020

Moclobemide in social phobia: a controlled dose-response trial

1 reference

12 December 2020

Trimipramine and maprotiline plasma levels during combined treatment with moclobemide in therapy-resistant depression

1 reference

12 December 2020

Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression

1 reference

12 December 2020

Moxonidine and cognitive function: interactions with moclobemide and lorazepam.

1 reference

12 December 2020

A fatality involving moclobemide, sertraline, and pimozide

1 reference

12 December 2020

A fatality due to moclobemide.

1 reference

12 December 2020

An uncommon fatality due to moclobemide and paroxetine.

1 reference

12 December 2020

Moclobemide and imipramine in chronic depression (dysthymia): an international double-blind, placebo-controlled trial. International Collaborative Study Group

1 reference

12 December 2020

An open trial of moclobemide in the treatment of post-traumatic stress disorder

1 reference

12 December 2020

Drug interactions of clinical significance with selective serotonin reuptake inhibitors

1 reference

12 December 2020

Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder

1 reference

12 December 2020

Social phobia: long-term treatment outcome and prediction of response--a moclobemide study

1 reference

12 December 2020

Moclobemide for anxiety disorders: a focus on moclobemide for panic disorder

1 reference

12 December 2020

Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview

1 reference

12 December 2020

Sumatriptan contraindications and the serotonin syndrome.

1 reference

12 December 2020

Selecting an Antidepressant for Use in a Patient with Epilepsy

1 reference

12 December 2020

Placebo-controlled trial of moclobemide in social phobia

1 reference

12 December 2020

Fatal serotonin syndrome caused by moclobemide-clomipramine overdose

1 reference

12 December 2020

The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson's disease.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic interactions between fluoxetine and moclobemide in the investigation of development of the "serotonin syndrome"

1 reference

12 December 2020

Antidepressant interactions with warfarin

1 reference

12 December 2020

Treatment of the serotonin syndrome with cyproheptadine.

1 reference

12 December 2020

Moclobemide-induced hypersexuality in patients with stroke and Parkinson's disease

1 reference

12 December 2020

Dimensional assessment of onset of action of antidepressants: a comparative study of moclobemide vs. clomipramine in depressed patients with blunted affect and psychomotor retardation

1 reference

12 December 2020

Antidepressants and suicide mortality

1 reference

12 December 2020

Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects.

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder.

1 reference

12 December 2020

Switching to moclobemide to reverse fluoxetine-induced sexual dysfunction in patients with depression.

1 reference

12 December 2020

Monoamine Oxidase Inhibitors

1 reference

12 December 2020

Selecting an antidepressant for use in a patient with epilepsy. Safety considerations

1 reference

12 December 2020

Identifiers

PubMed ID

12595913

1 reference

PubMed ID

12595913